

# Hormone Therapies to Strengthen Our Immune Resistance to Viral Infections, Including COVID-19

By Thierry Hertoghe, MD  
International Hormone Society


## Complete References

### Thyroid

1. Günel C, Başak HS, Güney E. The relationship between hypothyroidism and rhinitis. *Kulak Burun Bogaz Ihtis Derg.* 2010 Jul-Aug;20(4):163-8
2. Zhang J, Chen Y. Patients infected with avian influenza A H7N9 virus have abnormally low thyroid hormone levels. *Clin Lab.* 2014;60(7):1241-3
3. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. *Thyroid.* 2021 Jan;31(1):8-11
4. Wei L, Sun S, Xu CH, Zhang J, Xu Y, Zhu H, Peh SC, Korteweg C, McNutt MA, Gu J. Pathology of the thyroid in severe acute respiratory syndrome. *Hum Pathol.* 2007 Jan;38(1):95-102
5. Sun S, Wei L, Zhang J, Xu Y, He FJ, Gu J. [Pathology and immunohistochemistry of thyroid in severe acute respiratory syndrome]. *Zhonghua Yi Xue Za Zhi.* 2005 Mar 16;85(10):667-70
6. Bhawati Guha Majumder. NEW FACT: Faster Recovery From Coronavirus Made Possible With Experimental Thyroid Hormone Therapy. International business times; 2020, November 3, 2020 at <https://www.ibtimes.sg/new-fact-faster-recovery-coronavirus-made-possible-experimental-thyroid-hormone-therapy-53028>
7. Varedi M, Moattari A, Amirghofran Z, Karamizadeh Z, Feizi H. Effects of hypo- and hyperthyroid states on herpes simplex virus infectivity in the rat. *Endocr Res.* 2014;39(2):50-55. D
8. Hsia SV, Chen LH, Tseng HF. Receipt of thyroid hormone deficiency treatment and risk of herpes zoster. *Int J Infect Dis.* 2017 Jun;59:90-95
9. Thomas D, Karachaliou F, Kallergi K, Vlachopapadopoulou E, Antonaki G, Chatzimarkou F, Fotinou A, Kaldrymides P, Michalacos Herpes virus antibodies seroprevalence in children with autoimmune thyroid disease. *Endocrine.* 2008 Apr;33(2):171-5
10. Novis M, Vaisman M, Coelho HS. Thyroid function tests in viral chronic hepatitis. *Arq Gastroenterol.* 2001 Oct-Dec;38(4):254-60



11. Kano T, Kojima T, Takahashi T, Muto Y. Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. *Gastroenterol Jpn.* 1987 Jun;22(3):344-53
12. Mateiko GB, Dikić BN. The efficacy of the hormonal substitute therapy of adolescents with viral hepatitis A combined with thyroid hypofunction. *Vrach Delo.* 1990 Aug;(8):101-2
13. Liu L, Li P, Mi Y, Liu Y, Liu Y, Zhang P. Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B. *Medicine (Baltimore).* 2019 Nov;98(46):e17945
14. Itoh S, Yamaba Y, Oda T, Kawagoe K. Serum thyroid hormone, triiodothyronine, thyroxine, and triiodothyronine/thyroxine ratio in patients with fulminant, acute, and chronic hepatitis. *Am J Gastroenterol.* 1986 Jun;81(6):444-9
15. Shen Y, Wang XL, Xie JP, Shao JG, Lu YH, Zhang S, Qin G. Thyroid disturbance in patients with chronic hepatitis C infection: A systematic review and meta-analysis. *J Gastrointestin Liver Dis.* 2016 Jun;25(2):227-34
16. Mansour-Ghanaei F, Mehrdad M, Mortazavi S, Joukar F, Khak M, Atrkar-Roushan Z. Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage. *Ann Hepatol.* 2012 Sep-Oct;11(5):667-71
17. Jain G, Devpura G, Gupta BS. Abnormalities in the thyroid function tests as surrogate marker of advancing HIV infection in infected adults. *J Assoc Physicians India.* 2009 Jul;57:508-10



## Thymosin-alpha-1

18. Ershler WB, Gravenstein S, Geloo ZS. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. *Ann N Y Acad Sci.* 2007 Sep;1112:375-84.
19. Gao ZC, Zhu JH., Sun Y, Ding XL, Ma JS, Cui, Y. X., He QY. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. *Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine= Zhongguo weizhongbing jijiuyixue* 2003;15(6), 332-335
20. Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. *Clin Infect Dis.* 2020 Nov 19;71(16):2150-2157.
21. Mamedov MK, Safarova SM, Dadasheva AE. Impact of thymosin-alpha1 on reproduction of herpes simplex virus in cell system and on course of acute experimental infection in mice. *Georgian Med News.* 2012 Oct;(211):71-5.

22. Barinskiĭ, I. F., Alimbarova, L. M., Platonova, A. A., & Shmelev, V. A. (2004). Antiviral activity of human recombinant gamma-interferon and recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 on models of herpes-virus and cytomegalovirus infection in vitro. *Voprosy virusologii*, 49(5), 37-43.
23. Ji SM, Li LS, Sun QQ, Chen JS, Sha GZ, Liu ZH. Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation. *Transplant Proc.* 2007 Jan-Feb;39(1):115-9. (thymosin alpha1, (1.6 mg) subcutaneously every other day or every day)
24. Sherman KE, Jones CC, Goldstein AL, Naylor PH. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. *Viral Immunol.* 1991 Fall;4(3):195-9. Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii.
25. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, Sriplung H, Geater A, Qiao YW, Wu RX. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. *World J Gastroenterol.* 2006 Nov 7;12(41):6715-21
26. Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. *J Viral Hepat.* 2006 Dec;13(12):845-50.
27. Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M, Suzuki H, Martins EB. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. *J Viral Hepat.* 2005 May;12(3):300-6.
28. Liang YR, Guo Z, Jiang JH, Xiang BD, Li LQ. Thymosin  $\alpha$ 1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. *Oncol Lett.* 2016 Nov;12(5):3513-3518.
29. Jiang YF, Ma ZH, Zhao PW, Pan Y, Liu YY, Feng JY, Niu JQ. Effect of thymosin- $\alpha$ (1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B. *J Int Med Res.* 2010;38(6):2053-62.
30. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, Sriplung H, Geater A, Qiao YW, Wu RX. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. *World J Gastroenterol.* 2006 Nov 7;12(41):6715-21.
31. Panatto D1, Amicizia D, Lai PL, Camerini R, De Rosa A, Gasparini R. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. *J Prev Med Hyg.* 2011 Sep;52(3):111-5.
32. Ershler WB1, Gravenstein S, Geloo ZS. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. *Ann N Y Acad Sci.* 2007 Sep;1112:375-84.
33. Grandini E, Cannoletta F, Scuteri A, Fortini C, Loggi E, Cursaro C, Riili A, Di Donato R, Gramenzi A, Bernardi M, Andreone P. Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C. *Ann N Y Acad Sci.* 2010 Apr;1194:147-52.
34. Ciancio A, Andreone P, Kaiser S, Mangia A, Milella M, Solà R, Pol S, Tsianos E, De Rosa A, Camerini R, McBeath R, Rizzetto M. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? *J Viral Hepat.* 2012 Jan;19 Suppl 1:52-9.

35. Poo JL, Sánchez-Avila F, Kershenobich D, García-Samper X, Gongora J, Uribe M. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. *J Gastroenterol Hepatol.* 2004 Dec;19(12):S79-81.
36. Abbas Z, Hamid SS, Tabassum S, Jafri W. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin. *J Pak Med Assoc.* 2004 Nov;54(11):571-4.
37. Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E, D'Errico A, Spinoza M, Lorenzini S, Biselli M, Bernardi M. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. *J Viral Hepat.* 2004 Jan;11(1):69-73..
38. Rubinstein A, Novick BE, Sicklick MJ, Bernstein LJ, Incefy GS, Naylor PH, Goldstein AL. Circulating thymulin and thymosin-alpha 1 activity in pediatric acquired immune deficiency syndrome: in vivo and in vitro studies. *J Pediatr.* 1986 Sep;109(3):422-7. (children with acquired immune deficiency syndrome had elevated serum levels of thymosin-alpha 1)
39. Naylor PH, Friedman-Kien A, Hersh E, Erdos M, Goldstein AL. Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum. *Int J Immunopharmacol.* 1986;8(7):667-7643h
40. Ritter J, Sepetjan M, Monier JC. Lack of reactivity of anti-human immunodeficiency virus (HIV) P17/18 antibodies against alpha 1 thymosin and of anti-alpha 1 thymosin monoclonal antibody against P17/18 protein. *Immunol Lett.* 1987 Nov;16(2):97-100
41. Garaci E, Rocchi G, Perroni L, D'Agostini C, Soscia F, Grelli S, Mastino A, Favalli C. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection. *Int J Clin Lab Res.* 1994;24(1):23-8.
42. Chadwick D, Pido-Lopez J, Pires A, Imami N, Gotch F, Villacian JS, Ravindran S, Paton NI. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. *Clin Exp Immunol.* 2003 Dec;134(3):477-81.
- 43. Matteucci C, Minutolo A, Pollicita M, Balestrieri E, Grelli S, D'Ettorre G, Vullo V, Bucci I, Luchini A, Aquaro S, Sinibaldi-Vallebona P, Macchi B, Perno CF, Mastino A, Garaci E. Thymosin  $\alpha$  1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro. Expert Opin Biol Ther.** 2015;15 Suppl 1:S83-100.

## Cortisol

44. Bancos I, Hazeldine J, Chortis V, Hampson P, Taylor AE, Lord JM, Arlt W. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. *Eur J Endocrinol.* 2017 Apr;176(4):471-480.
45. Jefferies W McK. Safe uses of cortisol. Charles C Thomas Ed., Springfield I- Illinois - USA. 3rd Ed. 2004 p134-135
46. Skänse B, Miörner G: Asian influenza with adrenocortical insufficiency. *Lancet.* 1959; i: 1121-2
47. Plaza de los Reyes M, Cruz-Coke R, Orozco R, Matus I, Cristofafnini A: Influenza pneumonia treated with cortisone and antibiotics. *Lancet* 1957; ii: 845: 1122.

48. Rotem CE: Influenza pneumonia treated with cortisone and antibiotics. Lancet 1957; ii: 948.
49. Gunn W. Influenza pneumonia treated with cortisone and antibiotics. Lancet. 1957; ii: 1004.
50. Walter WC, Douglas AC, Leckie JWH, Pines A, Grant IWB: Respiratory complications of influenza. Lancet 1958; i:449-54.
51. Farr BM, Gwaltney JM Jr, Hendley JO, Hayden FG, Naclerio RM, McBride T, Doyle WJ, Sorrentino JV, Riker DK, Proud D. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis. 1990 Nov;162(5):1173-7.
52. Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Sep 2.
53. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. N Engl J Med. 2020 Jul 17;NEJMoa2021436.
54. Wassilew SW, Lilie M. Value of glucocorticoid treatment in herpes zoster. Z Hautkr. 1986 Jun 1;61(11):773-8.
55. Jefferies W McK. Chap. 9: Viral infections including the common cold, influenza, infectious mononucleosis and shingles. in: Safe uses of cortisol. Charles C Thomas Ed., Springfield I- Illinois - USA. 3rd Ed. 2004: p. 144
56. Zhang J, Yu HW, Li J, Zhu YK, Wang KF, Jia L, Meng QH. Reduced cortisol in the absence of bacterial infection in patients with hepatitis B virus cirrhosis. Genet Mol Res. 2015 Jul 17;14(3):7957-63.
57. Hannoun C, Fernandes Mv, Macieira-Coelho A. Effects of cortisone on in vitro viral infection. I. Inhibition of cytopathogenesis by polio, rabies and yellow fever viruses in human embryonic cells. Proc Soc Exp Biol Med. 1965 May;119:153-8
58. Ekpebegh CO, Ogbera AO, Longo-Mbenza B, Blanco-Blanco E, Awotedu A, Oluboyo P. Basal cortisol levels and correlates of hypoadrenalinism in patients with human immunodeficiency virus infection. Med Princ Pract. 2011;20(6):525-9.

## DHEA

59. Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med. 1997 Jul;25(7):1207-14
60. Loria RM, Padgett DA. Mobilization of cutaneous immunity for systemic protection against infections. Ann N Y Acad Sci. 1992 Apr 15;650:363-6
61. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). J Med Virol. 1988 Nov;26(3):301-14

62. Henderson E, Schwartz A, Pashko L, Abou-Gharbia M, Swern D. Dehydroepiandrosterone and 16 alpha-bromo-epiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. *Carcinogenesis*. 1981;2(7):683-6
63. Lutsenko MT, Andrievskaia IA, Dovzhikova IV. DHEA-s synthesis during pregnancy with cytomegalovirus infection. *Arkh Patol*. 2012 Jan-Feb;74(1):46-7
64. Loria RM, Padgett DA. Mobilization of cutaneous immunity for systemic protection against infections. *Ann N Y Acad Sci*. 1992 Apr 15;650:363-6
65. Mauboussin JM, Mahamat A, Peyrière H, Rouanet I, Fabbro-Peray P, Daures JP, Vincent D. Low plasma levels of dehydroepiandrosterone sulphate in HIV-positive patients coinfected with hepatitis C virus. *HIV Med*. 2004 May;5(3):151-7
66. de la Torre B, von Krogh G, Svensson M, Holmberg V. Blood cortisol and dehydroepiandrosterone sulphate (DHEAS) levels and CD4 T cell counts in HIV infection. *Clin Exp Rheumatol*. 1997 Jan-Feb;15(1):87-90
67. Christeff N, Nunez EA, Gougeon ML. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. *Ann N Y Acad Sci*. 2000;917:962-70
68. Christeff N, Melchior JC, Mammes O, Gherbi N, Dalle MT, Nunez EA. Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. *Nutrition*. 1999 Jul-Aug;15(7-8):534-9
69. Mulder JW, Frissen PH, Krijnen P, Endert E, de Wolf F, Goudsmit J, Masterson JG, Lange JM. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. *J Infect Dis*. 1992 Mar;165(3):413-8
70. Jacobson MA, Fusaro RE, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. *J Infect Dis*. 1991 Nov;164(5):864-8
71. de le Torre B, van Krogh G, Svensson M, Holmberg V. Blood cortisol and dehydroepiandrosterone sulphate (DHEAS) levels and CD4 T cell counts in HIV infection. *Clin Exp Rheumatol*. 1997 ; 15 (1) : 87-90
72. Henderson E, Yang JY, Schwartz A. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. *AIDS Res Hum Retroviruses*. 1992 May;8(5):625-31.
73. Yang JY, Schwartz A, Henderson EE. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro. *Biochem Biophys Res Commun*. 1994 Jun 30;201(3):1424-32.
74. Yang JY, Schwartz A, Henderson EE. Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA. *AIDS Res Hum Retroviruses*. 1993 Aug;9(8):747-54

## Melatonin

75. Ben-Nathan D, Maestroni GJ, Lustig S et al. () Protective effects of melatonin in mice infected with encephalitis viruses. *Arch. Virol*. 1995;140: 223-230
76. Maestroni GJ, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. *Ann N Y Acad Sci*. 1988;521:140-8.

77. Bonilla E, Rodon C, Valero N, Pons H, Chacin-Bonilla L, Garcia Tamayo J, Rodriguez Z, Medina-Leendertz S, Anez F. Melatonin prolongs survival of immunodepressed mice infected with the Venezuelan equine encephalomyelitis virus. *Trans R Soc Trop Med Hyg* 2001 Mar-Apr;95(2):207-10. Instituto de Investigaciones Clinicas, Universidad de Zulia, Maracaibo, Venezuela
78. Valero N, Mosquera J, Alcocer S, et al. Melatonin, minocycline and ascorbic acid reduce oxidative stress and viral titers and increase survival rate in experimental Venezuelan equine encephalitis. *Brain Res.* 2015;1622:368–376
79. Ellis LC. Melatonin reduces mortality from Aleutian disease in mink (*Mustela vison*). *J. Pineal Res.* 1996; 21: 214-217
80. Laliena A, San Miguel B, Crespo I et al. Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin. *J. Pineal Res.* 2012; 53: 270-278
81. Tunon MJ, San Miguel B, Crespo I et al. Melatonin treatment reduces endoplasmic reticulum stress and modulates the unfolded protein response in rabbits with lethal fulminant hepatitis of viral origin. *J. Pineal Res.* 2013; 55: 221-228
82. Crespo I, San Miguel B, Sanchez DI et al. Melatonin inhibits the sphingosine kinase 1/sphingosine-1-phosphate signaling pathway in rabbits with fulminant hepatitis of viral origin. *J. Pineal Res.* 2016; 61: 168-176
83. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ. COVID-19: Melatonin as a potential adjuvant treatment. *Life Sci.* 2020 Jun 1;250:117583
84. Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin “goes viral” *Melatonin Res.* 2020; 3(1) 43-57
85. Nunes Oda S, Pereira Rde S. Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir. *J Pineal Res.* 2008 May;44(4):373-8
86. Khazan M, Nasiri S, Riahi SM, Robati RM, Hedayati M. Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster. *J Med Virol.* 2020 Aug;92(8):1253-1259
87. Ahmadi-Motamayel F, Vaziri-Amjad S, Goodarzi MT, Samie L, Poorolajal J. Evaluation of salivary melatonin levels in HIV-positive patients: a historical cohort study. *Rev Recent Clin Trials.* 2017;12(3):168-173
88. Nunnari G, Nigro L, Palermo F, Leto D, Pomerantz RJ, Cacopardo B. Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels. *Infection.* 2003 Dec;31(6):379-82

## Estradiol

89. Robinson DP, Lorenzo ME, Jian W, Klein SL. Elevated 17 $\beta$ -estradiol protects females from influenza A virus pathogenesis by suppressing inflammatory responses. *PLoS Pathog.* 2011 Jul;7(7):e1002149
90. Davis SM, Sweet LM, Oppenheimer KH, Suratt BT, Phillippe M. Estradiol and progesterone influence on influenza infection and immune response in a mouse model. *Am J Reprod Immunol.* 2017 Oct;78(4).
91. Nguyen DC, Massoud F, Lu X, Scinicariello F, Sambhara S, Attanasio R. 17 $\beta$ -Estradiol restores antibody responses to an influenza vaccine in a postmenopausal mouse model. *Vaccine.* 2011 Mar 21;29(14):2515

92. Itaborahy RM, Mancini DA, de Medeiros SF. Response to the influenza vaccine based on estradiol use in menopausal women. *Vaccine*. 2016 Mar 8;34(11):1358-62
93. Adamek A, Kasprzak A, Seraszek A, Mikoś H, Bura A, Mozer-Lisewska I. Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. *Contemp Oncol (Pozn)*. 2012;16(3):234-9
94. Hayashida K, Shoji I, Deng L, Jiang DP, Ide YH, Hotta H. 17 $\beta$ -estradiol inhibits the production of infectious particles of hepatitis C virus. *Microbiol Immunol*. 2010 Nov;54(11):684-90
95. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. *J Infect Dis*. 2000 Sep;182(3):708-15

## Testosterone

96. Vom Steeg LG, Attreed SE, Zirkin B, Klein SL. Testosterone treatment of aged male mice improves some but not all aspects of age-associated increases in influenza severity. *Cell Immunol*. 2019 Nov;345:103988
97. Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Stanley TL, Hadigan C. Testosterone in men with chronic hepatitis C infection and after hepatitis C viral clearance. *Clin Infect Dis*. 2019 Aug 1;69(4):571-576
98. Neff GW, O'Brien CB, Shire NJ, DeManno A, Kahn S, Rideman E, Safdar K, Madariaga J, Rudich SR. Topical testosterone treatment for chronic allograft failure in liver transplant recipients with recurrent hepatitis C virus. *Transplant Proc*. 2004 Dec;36(10):3071-4
99. Gomes AR, Souteiro P, Silva CG, Sousa-Pinto B, Almeida F, Sarmento A, Carvalho D, Freitas P. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. *BMC Infect Dis*. 2016 Nov 3;16(1):628
100. Laan ETM, Prins JM, van Lunsen RHW, Nieuwkerk PT, Nievaard-Boon MAF. Testosterone insufficiency in human immunodeficiency virus-infected women: a cross-sectional study. *Sex Med*. 2019 Mar;7(1):72-79
101. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, Spreafico F, Greco GF, Cervi G, Pecoriello A, Magini A, Todisco T, Cipriani S, Maseroli E, Corona G, Salonia A, Lenzi A, Maggi M, De Donno G, Vignozzi L. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. *Andrology*. 2021 Jan;9(1):88-98.

